Bristol-Myers Squibb raises forecast as strong 2nd-qtr 2011 results beat forecasts

29 July 2011

US drug major Bristol-Myers Squibb (NYSE: BMY) yesterday reported second-quarter 2011 net profit of $902 million, or $0.52 a share, down nearly 3% due to higher taxes and increased costs for production, marketing and administration. Adjusted (non-GAPP) earnings were $971 million, or $0.56 a share. However, net sales for the quarter at $5.4 billion, increase 14%, or 10% excluding the impact of foreign exchange, compared to the same period a year ago.

The company still beat expectations; analysts surveyed by FactSet Research expected earnings of $0.55 cents a share, on revenue of $5.05 billion. B-MS is raising its 2011 GAAP EPS guidance range to $2.08 to $2.18 and its non-GAAP EPS range to $2.20 to $2.30.

US net sales increased 15% to $3.6 billion, while international net sales increased 13%, or 3% excluding foreign exchange impact, to $1.9 billion. The incremental impact in 2011 over 2010 of the two additional US health care reform provisions for new discounts associated with the Medicare Part D coverage gap and the annual pharmaceutical company fee decreased second quarter EPS by approximately $0.03, the New York-based firm noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical